Purpose: Patients with malignant pleural mesothelioma, a rapidly progressing malignancy
with a median survival time of 6 to 9 months, have previously responded poorly to …

Although malignant mesothelioma is not a classically immunogenic cancer, there is
abundant evidence for immune recognition. The relative ease of obtaining tumor tissue …

The present report reviews a number of recently published papers on a novel technology for
the cytosolic delivery of macromolecules named photochemical internalisation (PCI). PCI is …

BACKGROUND The incidence of malignant mesothelioma is increasing. There is the
perception that survival is worse in the UK than in other countries. However, it is important to …

Introduction Previously published results from a randomized phase III study of pemetrexed
plus cisplatin in patients with malignant pleural mesothelioma (MPM) demonstrated a …

Our previous phase II study of cisplatin and gemcitabine in malignant mesothelioma showed
a 47.6%(95% CI 26.2–69.0%) response rate with symptom improvement in responding …

A method, system, and computer program product for automated and semi-automated
measurements of pleural space and/or pleural thickening in thoracic CT images to identify …

Background:: A phase III trial in patients with malignant pleural mesothelioma demonstrated
a survival advantage for pemetrexed plus cisplatin compared with single-agent cisplatin …

Rationale: Exploiting the immunostimulatory capacities of dendritic cells holds great promise
for cancer immunotherapy. Currently, dendritic cell–based immunotherapy is evaluated …

Immunotherapy against a variety of malignancies, including pleural-based malignancies,
has shown promise in animal models and early human clinical trials, but successful efforts …